Genome Editing and Engineering (eBook, PDF)

From TALENs, ZFNs and CRISPRs to Molecular Surgery
Redaktion: Appasani, Krishnarao

• Format: PDF

Produktbeschreibung

Recent advances in genome editing tools using endonucleases such as TALENs, ZFNs, and CRISPRs, combined with genomic engineering technologies, have opened up a wide range of opportunities from applications in the basic sciences and disease biology research, to the potential for clinical applications and the development of new diagnostic tools. This complete guide to endonuclease-based genomic engineering gives readers a thorough understanding of this rapidly expanding field. Chapters cover the discovery, basic science, and application of these techniques, focusing particularly on their potential relevance to the treatment of cancer, and cardiovascular and immunological disease. The final section discusses the legal and ethical issues which accompany the technology. Providing authoritative coverage of the potential that genome editing and engineering have, this is an ideal reference for researchers and graduate students and those working in the biotechnology and pharmaceutical industries, as well as in a clinical setting.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Cambridge University Press
• Erscheinungstermin: 23. August 2018
• Englisch
• ISBN-13: 9781316767122
• Artikelnr.: 53368296

Inhaltsangabe

List of contributors; Forewords; Preface; List of abbreviations; Part I.
Biology of Endonucleases (Zinc-Finger Nuclease, TALENs and CRISPRs) and
Regulatory Networks: 1. Introduction to genome editing and engineering:
from Talens, ZFNs and CRISPRs to molecular surgery; 2. Targeted genome
editing techniques in C. elegans and other nematode species; 3. Unbiased
detection of off-target cleavage by CRISPR-Cas9 and TALENs using
integrase-defective lentiviral vectors; 4. In vivo studies of miRNA target
interactions using site-specific genome engineering; 5. Don't kill the
messenger: employing genome editing to study regulatory RNA interactions;
Part II. Genome Editing in Model Organisms: 6. Genome editing in the
crustacean Daphnia magna using CRISPR/Cas and TALEN systems; 7.
Leapfrogging: a method for targeting genome editing to the germline; 8.
Genome editing with desired mutations (knock-in) by CRISPR in model
organisms; 9. Genetically engineered pig models for human diseases using
ZFNs, TALENs and CRISPR-Cas9; 10. Gene editing to create agricultural and
biomedical swine models; 11. Generation of new model cell lines using ssODN
knock-in donors and FACS-based genome editing; Part III. Technology
Development and Screening: 12. CRISPR genome editing in mice; 13. Detection
of insertion/deletion (indel) events after genome targeting: pros and cons
of the available methods; 14. Application of TAL proteins and the CRISPR
system to purification of specific genomic regions for locus-specific
identification of chromatin-associated molecules; 15. Application of CRISPR
for pooled, vector-based functional genomic screening in mammalian cell
lines; 16. Generation and utilization of CRISPR/Cas9 screening libraries in
mammalian cells; Part IV. Genome Editing in Stem Cells and Regenerative
Biology: 17. Targeted genome editing using nuclease assisted vector
integration; 18. Genome engineering using Sleeping Beauty transposition in
vertebrates; 19. Genome editing of pluripotent stem cells; 20. Principles
for targeting adult tissue stem cells to achieve durable gene and
gene-editing therapies; 21. Therapeutic genome editing in human
hematopoietic stem and progenitor cells; Part V. Genome Editing in Disease
Biology: 22. CRISPR/Cas9-Based in vivo models of cancer; 23. Inducible
CRISPR-based genome editing for the characterization of cancer genes; 24.
Genome editing for retinal diseases; 25. Manipulation of long non-coding
RNAs in cardiovascular disease using genome-editing technology; 26. Gene
silencing, disruption and latency reactivation with RNA-based and gene
editing CRISPR/Cas, ZFN and TALEN technologies for HIV-1/AIDS therapies;
27. Use of the CRISPR-Cas9 system for genome editing of immune system
cells, defense against HIV-1 and cancer therapies; 28. Harnessing
therapeutic potential of long non-coding RNAs in immunity; Part VI. Legal
(Intelluctual Property) and Bioethical Issues of Genome Editing: 29.
Patening of CRISPR-based inventions; 30. Patent, ownership, and licensing
issues of CRISPR-based genome editing: impact on universities and their
licensees; 31. The ethics of human genome editing; 32. Regulating human
genome editing: negotiating ethical concerns through science and policy;
Index.